Enlivex (ENLV) Capital Expenditures (2013 - 2025)
Enlivex (ENLV) posted quarterly Capital Expenditures of $128000.0 for Q4 2025, down 25.15% year-over-year from $171000.0 in Q4 2024, and up 709.52% quarter-over-quarter from -$21000.0 in Q3 2025.
Enlivex (ENLV) Capital Expenditures (2013 - 2025) Analysis & Trends
Enlivex's Capital Expenditures history runs 13 years deep, the most recent figure standing at $128000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures fell 25.15% year-over-year to $128000.0; the TTM figure through Dec 2025 stood at $68000.0 (down 33.98% YoY), while the FY2025 annual figure was $68000.0, down 33.98% from the prior year.
- Capital Expenditures for Q4 2025 stood at $128000.0, up from -$21000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $13.7 million in Q4 2022, with the low at -$3.4 million in Q2 2022.
- The 5-year median for Capital Expenditures is -$30500.0 (2023), against an average of $507700.0.
- Peak annual rise in Capital Expenditures reached 516.28% in 2022, while the deepest fall reached 1036.79% in 2022.
- Enlivex's Capital Expenditures stood at $2.2 million in 2021, then surged by 516.28% to $13.7 million in 2022, then plunged by 96.6% to $465000.0 in 2023, then tumbled by 63.23% to $171000.0 in 2024, then retreated by 25.15% to $128000.0 in 2025.
- Business Quant data shows ENLV's Capital Expenditures at $128000.0 in Q4 2025, -$21000.0 in Q3 2025, and -$7000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | 128,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 128,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -32,000.00 |
| Mar 31, 2025 | -32,000.00 |
| Dec 31, 2024 | 171,000.00 |
| Dec 31, 2024 | 171,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -16,000.00 |
| Jun 30, 2024 | -16,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Dec 31, 2023 | 465,000.00 |
| Dec 31, 2023 | 465,000.00 |
| Sep 30, 2023 | -29,000.00 |
| Sep 30, 2023 | -29,000.00 |